NANOBIOTIX 31.080 € (+3,74 %) SERGEFERRARI GROUP 8.000 € (+2,56 %) TOTALENERGIES 68.360 € (-1,31 %) SERGEFERRARI GROUP 8.000 € (+2,56 %) 
ADYEN 824.900 € (+0,37 %) EXAIL TECHNOLOGIES 116.700 € (+25,28 %) CAPGEMINI 89.680 € (+1,33 %) 
SHELL PLC 33.700 € (-1,00 %) BUREAU VERITAS 26.120 € (+0,66 %) HERMES INTL 1 626.000 € (+0,77 %) PHILIPS KON 23.890 € (-0,17 %) SANOFI 75.070 € (+1,78 %) ASML HOLDING 1 578.200 € (-0,99 %) BOLLORE 4.100 € (+0,15 %) VEOLIA ENVIRON. 36.230 € (+0,22 %) SMCP 5.015 € (+0,30 %) 
FLOW TRADERS 25.580 € (-0,93 %) ASM INTERNATIONAL 948.000 € (-4,34 %) AYVENS 11.460 € (-0,87 %) CSG 12.682 € (+2,69 %) BE SEMICONDUCTOR 282.700 € (-2,21 %) SCOR SE 31.980 € (+0,50 %) STMICROELECTRONICS 62.580 € (-3,81 %) ESSILORLUXOTTICA 168.650 € (+1,54 %) CRCAM TOURAINE CCI 138.500 € (-0,93 %) LISI 66.100 € (-0,15 %) LVMH 495.750 € (+0,27 %) BOUYGUES 49.750 € (-0,78 %) 
DSM FIRMENICH AG 79.980 € (-0,65 %) NEXANS 141.100 € (-3,75 %) STELLANTIS NV 5.024 € (-1,95 %) THALES 216.500 € (-0,87 %) UMG 18.355 € (+0,71 %) NN GROUP 76.320 € (-0,29 %) AHOLD DEL 35.430 € (+0,85 %) 2CRSI 27.520 € (+8,01 %) SODEXO 51.250 € (-0,10 %) SOITEC 114.350 € (+1,87 %) TKH GROUP 43.620 € (+1,73 %) LNA SANTE 34.000 € (+3,03 %) OVH 13.600 € (+1,49 %) BAM GROEP KON 12.550 € (-1,18 %) AMG 32.900 € (-1,56 %) EUROFINS SCIENT. 68.960 € (+1,00 %) CEGEDIM 11.040 € (-1,43 %) AALBERTS NV 38.980 € (-1,66 %) DANONE 72.120 € (+3,06 %) ALSTOM 15.380 € (-1,94 %) REXEL 36.860 € (-1,18 %) RELX 27.440 € (-0,29 %) HAFFNER ENERGY 0.217 € (-2,25 %) ERAMET 45.160 € (-1,40 %) SAINT GOBAIN 80.600 € (-1,42 %) BNP PARIBAS ACT.A 101.120 € (-1,83 %) RUBIS 31.540 € (+0,64 %) JCDECAUX 19.050 € (+1,33 %) PERNOD RICARD 65.960 € (-0,06 %) SAVENCIA 66.600 € (0,00 %) AIRBUS 191.900 € (-1,63 %) ALTEN 53.400 € (+1,81 %) |
10/01/2023 12:10
EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Strategic Company Decision BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing) Zwingenberg, Germany BRAIN Biotech AG (“BRAIN”) announces that at the Supervisory Board meeting held today, the Executive Management Board of the company with the consent of the Supervisory Board decided to prioritize the development of therapeutic applications of the genome editing activities bundled under the brand name Akribion Genomics, this includes potential applications in oncology. The mode of action of the BRAIN nucleases selected for this purpose allows both the targeted enrichment and depletion by selective destruction of cells. This may open up fields of application in the area of therapeutics with considerable market potential. Akribion Genomics is currently establishing a partner network for the further development of this platform technology in therapeutic, diagnostic and industrial fields of application.
Information and Explanation of the Issuer to this announcement: About BRAIN Biotech BRAIN Biotech AG is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success. - BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group. - As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. BRAIN Biotech´s products and services target at least five of the UN SDGs directly. - Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394). 10-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
1530979 10-Jan-2023 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière